Antipsychotic doses among community-dwelling persons with Alzheimer disease in Finland

Journal of Clinical Psychopharmacology

Volumn 34, Issue 4, 2014, Pages 435-440

  Taipale, Heidi ^a   Koponen, Marjaana ^a   Tanskanen, Antti ^b,c   Tolppanen, Anna Maija ^a   Tiihonen, Jari ^a,b   Hartikainen, Sirpa ^a  

^a UNIVERSITY OF EASTERN FINLAND   (Finland)

^b KAROLINSKA INSTITUTE   (Sweden)

^c NATIONAL PUBLIC HEALTH INSTITUTE   (Finland)

Author keywords

Alzheimer's disease; antipsychotics; dose; older persons

Indexed keywords

ATYPICAL ANTIPSYCHOTIC AGENT; HALOPERIDOL; LEVOMEPROMAZINE; MELPERONE; NEUROLEPTIC AGENT; OLANZAPINE; PERICIAZINE; PERPHENAZINE; QUETIAPINE; RISPERIDONE; SULPIRIDE;

AGED; ALZHEIMER DISEASE; ARTICLE; CHARLSON COMORBIDITY INDEX; COHORT ANALYSIS; CONTROLLED STUDY; DOSAGE SCHEDULE COMPARISON; DRUG MEGADOSE; FEMALE; FINLAND; FOLLOW UP; HOSPITAL DISCHARGE; HUMAN; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MEDICAL HISTORY; MONOTHERAPY; OFF LABEL DRUG USE; PRESCRIPTION; PRIORITY JOURNAL; DEMOGRAPHY; DOSE RESPONSE; PSYCHOLOGY; VERY ELDERLY;

AGED, 80 AND OVER; ALZHEIMER DISEASE; ANTIPSYCHOTIC AGENTS; COHORT STUDIES; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FINLAND; FOLLOW-UP STUDIES; HUMANS; MALE; RESIDENCE CHARACTERISTICS;

EID: 84903726070     PISSN: 02710749     EISSN: 1533712X     Source Type: Journal    
DOI: 10.1097/JCP.0000000000000133     Document Type: Article

References (35)

1. Laitinen ML, Bell JS, Lavikainen P, et al. Nationwide study of antipsychotic use among community-dwelling persons with Alzheimer's disease in Finland. Int Psychogeriatr. 2011;23:1623-1631.
2. Johnell K, Religa D, Eriksdotter M. Differences in drug therapy between dementia disorders in the Swedish dementia registry: a nationwide study of over 7,000 patients. Dement Geriatr Cogn Disord. 2013;35: 239-248.
3. Martinez C, Jones RW, Rietbrock S. Trends in the prevalence of antipsychotic drug use among patients with Alzheimer's disease and other dementias including those treated with antidementia drugs in the community in the UK: a cohort study. BMJ Open. 2013;3:e002080.
4. Gurwitch JH. Start low and go slow: dosing of antipsychotic medications in elderly patients with dementia. Arch Intern Med. 1995;155:2017-2018.
5. APAWork Group on Alzheimer's Disease and other Dementias, Rabins PV, Blacker D, et al. American psychiatric association practice guideline for the treatment of patients with Alzheimer's disease and other dementias. Second edition. Am J Psychiatry. 2007;164(suppl 12):5-56.
6. Working group set up by the Finnish Medical Society Duodecim, Societas Gerontologica Fennica, the Finnish Neurological Society, Finnish Psychogeriatric Association and the Finnish Association for General Practice. Memory disorders. Current care guideline. 2010. Available at: http://www.kaypahoito.fi. Accessed July 1, 2013.
7. Rochon PA, Stukel TA, Sykora K, et al. Atypical antipsychotics and parkinsonism. Arch Intern Med. 2005;165:1882-1888. (Pubitemid 41352083)
8. Gill SS, Rochon PA, Herrmann N, et al. Atypical antipsychotic drugs and risk of ischaemic stroke: population based retrospective cohort study. BMJ. 2005;330:445.
9. Mittal V, Kurup L, Williamson D, et al. Risk of cerebrovascular adverse events and death in elderly patients with dementia when treated with antipsychotic medications: a literature review of evidence. Am J Alzheimers Dis Other Demen. 2011;26:10-28.
10. Schneider LS, Dagerman KS, Insel P. Risk of death with atypical antipsychotic drug treatment for dementia: meta-analysis of randomized placebo-controlled trials. JAMA. 2005;294:1934-1943. (Pubitemid 41464695)
11. Barbui C, Biancosino B, Esposito E, et al. Factors associated with antipsychotic dosing in psychiatric inpatients: a prospective study. Int Clin Psychopharmacol. 2007;22:221-225. (Pubitemid 46801945)
12. Sim K, Su HC, Fujii S, et al. High-dose antipsychotic use in schizophrenia: a comparison between the 2001 and 2004 Research on East Asia Psychotropic Prescription (REAP) studies. Br J Clin Pharmacol. 2009;67:110-117.
13. Xiang YT, Li Y, Correll CU, et al. Common use of high doses of antipsychotic medications in older Asian patients with schizophrenia (2001-2009) [published online ahead of print August 13, 2013]. Int J Geriatr Psychiatr. 2013.
14. Bronskill SE, Anderson GM, Sykora K, et al. Neuroleptic drug therapy in older adults newly admitted to nursing homes: incidence, dose, and specialist contact. J Am Geriatr Soc. 2004;52:749-755. (Pubitemid 38596494)
15. Gustafsson M, Karlsson S, Lovheim H. Inappropriate long-term use of antipsychotic drugs is common among people with dementia living in specialized care units. BMC Pharmacol Toxicol. 2013;14:10.
16. Tolppanen AM, Taipale H, Koponen M, et al. Use of existing data sources in clinical epidemiology: Finnish health care registers in Alzheimer's disease researchVthe medication use among persons with Alzheimer's disease (MEDALZ-2005) study. Clin Epidemiol. 2013;5:277-285.
17. McKhann G, Drachman D, Folstein M, et al. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDAwork group under the auspices of Department of Health and Human Services Task Force on Alzheimer's disease. Neurology. 1984;34:939-944. (Pubitemid 14076461)
18. WHO Collaborating Centre for Drug Statistics Methodology. The Anatomical Therapeutic Chemical Classification System. Available at: http://www.whocc.no/ atc-ddd-index/. Accessed May 22, 2013.
19. WHO Collaborating Centre for Drug Statistics Methodology. Defined daily dose. Available at: http://www.whocc.no/ddd/ definition-and-general-considera/. Accessed September 3, 2013.
20. Tiihonen J, Lonnqvist J, Wahlbeck K, et al. 11-Year follow-up of mortality in patients with schizophrenia: a population-based cohort study (FIN11 study). Lancet. 2009;374:620-627.
21. Purhonen M, Koponen H, Tiihonen J, et al. Outcome of patients after market withdrawal of thioridazine: a retrospective analysis in a nationwide cohort. Pharmacoepidemiol Drug Saf. 2012;21:1227-1231.
22. Finnish Medicines Agency. Summaries of product characteristics of drugs marketed in Finland. Available at: http://www.fimea.fi/medicines/ fimeaweb. Accessed May 8, 2013.
23. Charlson ME, Pompei P, Ales KL, et al. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40:373-383. (Pubitemid 17055592)
24. Rochon PA, Gruneir A, Gill SS, et al. Older men with dementia are at greater risk than women of serious events after initiating antipsychotic therapy. J Am Geriatr Soc. 2013;61:55-61.
25. Komossa K, Rummel-Kluge C, Schwartz S, et al. Risperidone versus other atypical antipsychotics for schizophrenia. Cochrane Database Syst Rev. 2011:CD006626.
26. Franz M, Ranger J, Hanewald B, et al. Influences on therapist's decisions for neuroleptic treatment in schizophrenia: the role of characteristics of the patient and the physician. Pharmacopsychiatry. 2012;45:261-268.
27. Uchida H, Mamo DC, Mulsant BH, et al. Increased antipsychotic sensitivity in elderly patients: evidence and mechanisms. J Clin Psychiatry. 2009;70:397-405.
28. Lyketsos CG, Carrillo MC, Ryan JM, et al. Neuropsychiatric symptoms in Alzheimer's disease. Alzheimers Dement. 2011;7:532-539.
29. Ott BR, Lapane KL, Gambassi G, and for the SAGE Study Group. Gender differences in the treatment of behavior problems in Alzheimer's disease. Neurology. 2000;54:427-432. (Pubitemid 30078077)
30. Coe HV, Hong IS. Safety of low doses of quetiapine when used for insomnia. Ann Pharmacother. 2012;46:718-722.
31. Wine JN, Sand C, Caballero J. Effects of quetiapine on sleep in nonpsychiatric and psychiatric conditions. Ann Pharmacother. 2009;43:707-713.
32. Setoguchi S, Wang PS, Alan Brookhart M, et al. Potential causes of higher mortality in elderly users of conventional and atypical antipsychotic medications. J Am Geriatr Soc. 2008;56:1644-1650.
33. Rossom RC, Rector TS, Lederle FA, et al. Are all commonly prescribed antipsychotics associated with greater mortality in elderly male veterans with dementia? J Am Geriatr Soc. 2010;58:1027-1034.
34. Schneeweiss S, Setoguchi S, Brookhart A, et al. Risk of death associated with the use of conventional versus atypical antipsychotic drugs among elderly patients. CMAJ. 2007;176:627-632. (Pubitemid 46426056)
35. Rikala M, Hartikainen S, Sulkava R, et al. Validity of the Finnish Prescription Register for measuring psychotropic drug exposures among elderly Finns: a population-based intervention study. Drugs Aging. 2010;27:337-349.